n.a. (BPAX)

55.05
0.69 1.24
NASDAQ
Prev Close 55.74
Open 56.64
Day Low/High 54.22 / 56.64
52 Wk Low/High 12.79 / 56.99
Volume 182.41K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioSante Pharmaceuticals Receives NASDAQ Delisting Determination Letter

BioSante Pharmaceuticals Receives NASDAQ Delisting Determination Letter

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that on June 20, 2013, it received a letter from NASDAQ informing BioSante that, since the merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,...

BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Completion Of Merger

BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Completion Of Merger

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that it has completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders To Vote “FOR” Proposed Merger With ANI Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders To Vote “FOR” Proposed Merger With ANI Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today sent a letter to stockholders in connection with its proposed merger with ANI Pharmaceuticals, Inc.

BioSante Pharmaceuticals Announces Adjournment Of Its Stockholders Meeting Until April 12, 2013

BioSante Pharmaceuticals Announces Adjournment Of Its Stockholders Meeting Until April 12, 2013

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger

Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Glass, Lewis & Co.

BioSante Pharmaceuticals Provides Merger Update And Reports 2012 Financial Results

BioSante Pharmaceuticals Provides Merger Update And Reports 2012 Financial Results

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today provided an update on the Company’s proposed merger transaction with ANI Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones In Recommending “FOR” BioSante/ANI Merger

Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones In Recommending “FOR” BioSante/ANI Merger

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that ISS PROXY ADVISORY SERVICES, an independent proxy advisory firm, has recommended that BioSante stockholders vote “FOR” the adoption of the ...

Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante And ANI Merger

Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante And ANI Merger

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Egan-Jones Proxy Services, an independent proxy advisory firm, has recommended that BioSante stockholders vote “FOR” the adoption of the ...

BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Special Meetings Of Stockholders To Consider Proposed Merger

BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Special Meetings Of Stockholders To Consider Proposed Merger

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

The Worst Biotech CEO of 2012 Is...

The Worst Biotech CEO of 2012 Is...

Cell Therapeutics' Jim Bianco Wins! Amarin CEO Joe Zakrzewski tries to steal election with last-minute plot.

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Readers get to decide which of the CEOs from BioSante, BioCryst, Peregrine or Cell Therapeutics deserve the dishonor.

The Next Big Thing in Biotech: Worst CEO Candidates

The Next Big Thing in Biotech: Worst CEO Candidates

Adam Feuerstein, senior columnist for TheStreet, is assembling candidates for the Worst Biotech CEO of 2012 award.

BioSante Pharmaceuticals Reports Third Quarter Financial Results And Merger Update

BioSante Pharmaceuticals Reports Third Quarter Financial Results And Merger Update

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported on its cash balance as of September 30, 2012 and financial results for the third quarter of 2012 and provided an update on the Company’s previously ...

BioSante Pharmaceuticals, Inc. To Present At BIO Investor Forum

BioSante Pharmaceuticals, Inc. To Present At BIO Investor Forum

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Stephen M.

BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Merger Agreement

BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Merger Agreement

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

4 Biotech Stocks Under $10 Soaring Higher

4 Biotech Stocks Under $10 Soaring Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioSante Pharmaceuticals Announces Positive LibiGel® Phase III Safety Data Review And Decision To Conclude The Safety Study

BioSante Pharmaceuticals Announces Positive LibiGel® Phase III Safety Data Review And Decision To Conclude The Safety Study

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that the independent Data Monitoring Committee (DMC) has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast...

BioSante Pharmaceuticals, Inc. To Present At Stifel Nicolaus Healthcare Conference And Rodman & Renshaw Global Investment Conference

BioSante Pharmaceuticals, Inc. To Present At Stifel Nicolaus Healthcare Conference And Rodman & Renshaw Global Investment Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M.

BioSante Pharmaceuticals Closes $3,475,000 Registered Direct Offering

BioSante Pharmaceuticals Closes $3,475,000 Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the closing of the sale of 2,359,932 shares of its common stock and warrants to purchase up to 1,179,966 additional shares of its common stock in a ...

BioSante Pharmaceuticals To Raise $3,475,000 In Registered Direct Offering

BioSante Pharmaceuticals To Raise $3,475,000 In Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has received a commitment from an institutional investor to purchase $3,475,000 of securities in a registered direct offering.

5 Biotech Stocks Under $5 Blasting Off

5 Biotech Stocks Under $5 Blasting Off

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioSante Pharmaceuticals Reports Second Quarter Financial Results And Pipeline Update

BioSante Pharmaceuticals Reports Second Quarter Financial Results And Pipeline Update

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported on its cash balance as of June 30, 2012, its financial results for the second quarter of 2012 and provided an update on the Company’s pipeline.

BioSante Pharmaceuticals Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

BioSante Pharmaceuticals Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that it has received notice from The NASDAQ Stock Market indicating that BioSante has regained compliance with the minimum bid price requirement for...

BioSante Execs Use Failed Libigel To Keep Paychecks Rolling In

BioSante Execs Use Failed Libigel To Keep Paychecks Rolling In

BioSante's plan to re-do failed Libigel clinical trials is just an excuse to perpetuate lavish executive salaries

BioSante Pharmaceuticals Announces New LibiGel® Phase III Efficacy Trials

BioSante Pharmaceuticals Announces New LibiGel® Phase III Efficacy Trials

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials.

BioSante Pharmaceuticals, Inc. To Present At Jefferies Global Healthcare Conference

BioSante Pharmaceuticals, Inc. To Present At Jefferies Global Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Stephen M.